Ikarian Capital’s CASI Pharmaceuticals CASI Stock Holding History

Ikarian Capital’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-132,014	Closed	-$378K	–	119
2022 Q2	$378K	Sell	132,014 -2	-0%	-$9	0.07%	107
2022 Q1	$1.07M	Buy	132,016 +9,709	+8%	+$76.3K	0.14%	97
2021 Q4	$978K	Hold	122,307	–	–	0.15%	101
2021 Q3	$1.46M	Sell	122,307 -4,508	-4%	-$61K	0.1%	141
2021 Q2	$1.97M	Hold	126,815	–	–	0.16%	129
2021 Q1	$3.04M	Hold	126,815	–	–	0.1%	171
2020 Q4	$3.74M	Sell	126,815 -27,176	-18%	-$591K	0.16%	113
2020 Q3	$2.36M	Buy	153,991 +50,000	+48%	+$942K	0.17%	106
2020 Q2	$2.6M	Hold	103,991	–	–	0.21%	96
2020 Q1	$2.12M	Buy	+103,991	New	+$2.48M	0.16%	94

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ikarian Capital's CASI Position: Q3 2022 in Review

Ikarian Capital sold out of CASI Pharmaceuticals (CASI) in Q3 2022, closing a stake of 132,014 shares — an estimated $378K sold.

Ikarian Capital first reported a position in CASI in Q1 2020 and held it in 10 quarters. The position peaked at $3.74M in Q4 2020. 24 funds tracked by Wall St. Rank hold CASI as of Q3 2022.

Ikarian Capital reported no remaining CASI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 132,014 CASI Pharmaceuticals shares in Q3 2022, an estimated $378K.
Ikarian Capital first reported a position in CASI Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Ikarian Capital's CASI Pharmaceuticals position peaked at $3.74M in Q4 2020.
24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.